Germline BRCA1 mutations increase prostate cancer risk

被引:219
|
作者
Leongamornlert, D. [1 ]
Mahmud, N. [1 ]
Tymrakiewicz, M. [1 ]
Saunders, E. [1 ]
Dadaev, T. [1 ]
Castro, E. [1 ]
Goh, C. [1 ]
Govindasami, K. [1 ]
Guy, M. [1 ]
O'Brien, L. [1 ]
Sawyer, E. [1 ]
Hall, A. [1 ]
Wilkinson, R. [1 ]
Easton, D. [2 ]
Goldgar, D. [3 ]
Eeles, R. [1 ,4 ]
Kote-Jarai, Z. [1 ]
机构
[1] Inst Canc Res, Oncogenet Team, Sutton SM2 5NG, Surrey, England
[2] Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Strangeways Lab, Cambridge CB1 8RN, England
[3] Univ Utah, Dept Dermatol, Salt Lake City, UT 84132 USA
[4] Royal Marsden NHS Fdn Trust, Sutton SM2 5NG, Surrey, England
关键词
prostate cancer; BRCA1; gene; mutation screening; cancer risk; GENETIC-VARIANTS; OVARIAN-CANCER; MISSENSE MUTATIONS; HEREDITARY BREAST; CPG METHYLATION; CARRIERS; DATABASE; SUSCEPTIBILITY; ALGORITHM; FAMILIES;
D O I
10.1038/bjc.2012.146
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Prostate cancer (PrCa) is one of the most common cancers affecting men but its aetiology is poorly understood. Family history of PrCa, particularly at a young age, is a strong risk factor. There have been previous reports of increased PrCa risk in male BRCA1 mutation carriers in female breast cancer families, but there is a controversy as to whether this risk is substantiated. We sought to evaluate the role of germline BRCA1 mutations in PrCa predisposition by performing a candidate gene study in a large UK population sample set. METHODS: We screened 913 cases aged 36-86 years for germline BRCA1 mutation, with the study enriched for cases with an early age of onset. We analysed the entire coding region of the BRCA1 gene using Sanger sequencing. Multiplex ligation-dependent probe amplification was also used to assess the frequency of large rearrangements in 460 cases. RESULTS: We identified 4 deleterious mutations and 45 unclassified variants (UV). The frequency of deleterious BRCA1 mutation in this study is 0.45%; three of the mutation carriers were affected at age <= 65 years and one developed PrCa at 69 years. Using previously estimated population carrier frequencies, deleterious BRCA1 mutations confer a relative risk of PrCa of similar to 3.75-fold, (95% confidence interval 1.02-9.6) translating to a 8.6% cumulative risk by age 65. CONCLUSION This study shows evidence for an increased risk of PrCa in men who harbour germline mutations in BRCA1. This could have a significant impact on possible screening strategies and targeted treatments. British Journal of Cancer (2012) 106, 1697-1701. doi:10.1038/bjc.2012.146 www.bjcancer.com Published online 19 April 2012 (C) & 2012 Cancer Research UK
引用
收藏
页码:1697 / 1701
页数:5
相关论文
共 50 条
  • [1] Germline BRCA1 mutations increase prostate cancer risk
    D Leongamornlert
    N Mahmud
    M Tymrakiewicz
    E Saunders
    T Dadaev
    E Castro
    C Goh
    K Govindasami
    M Guy
    L O'Brien
    E Sawyer
    A Hall
    R Wilkinson
    D Easton
    D Goldgar
    R Eeles
    Z Kote-Jarai
    [J]. British Journal of Cancer, 2012, 106 : 1697 - 1701
  • [2] BRCA1 mutations increase risk of prostate cancer
    Bennet, Neil
    [J]. LANCET ONCOLOGY, 2012, 13 (06): : E233 - E233
  • [3] Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
    Pawel Rajwa
    Fahad Quhal
    Benjamin Pradere
    Giorgio Gandaglia
    Guillaume Ploussard
    Michael S. Leapman
    John L. Gore
    Andrzej Paradysz
    Derya Tilki
    Axel S. Merseburger
    Todd M. Morgan
    Alberto Briganti
    Ganesh S. Palapattu
    Shahrokh F. Shariat
    [J]. Nature Reviews Urology, 2023, 20 : 205 - 216
  • [4] Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
    Rajwa, Pawel
    Quhal, Fahad
    Pradere, Benjamin
    Gandaglia, Giorgio
    Ploussard, Guillaume
    Leapman, Michael S.
    Gore, John L.
    Paradysz, Andrzej
    Tilki, Derya
    Merseburger, Axel S.
    Morgan, Todd M.
    Briganti, Alberto
    Palapattu, Ganesh S.
    Shariat, Shahrokh F.
    [J]. NATURE REVIEWS UROLOGY, 2023, 20 (04) : 205 - 216
  • [5] Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients
    Oliva, Lucia
    Lozano, Rebeca
    Llacer, Casilda
    Aragon, Isabel
    Pajares, Bella, I
    Saez, Maria Isabel
    Herrera-Imbroda, Bernardo
    Montesa, Alvaro
    Hernandez, David
    Villatoro, Rosa
    Otero, Ana
    Correa, Raquel
    Grau, Gala
    Peinado, Pablo
    Isabel Pacheco, Maria
    Garcia-Galisteo, Emilio
    Rueda, Antonio
    Javier Machuca, Francisco
    Alba, Emilio
    Marquez-Aragones, Antonia
    Olmos, David
    Castro, Elena
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (02): : 315 - 318
  • [6] Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2
    Park, Boyoung
    Dowty, James G.
    Ahn, Choonghyun
    Win, Aung K.
    Kim, Sung-Won
    Lee, Min Hyuk
    Lee, Jong Won
    Kang, Eunyoung
    Hopper, John L.
    Park, Sue K.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (03) : 659 - 665
  • [7] Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
    Elżbieta Złowocka-Perłowska
    Aleksandra Tołoczko-Grabarek
    Steven A. Narod
    Jan Lubiński
    [J]. Hereditary Cancer in Clinical Practice, 20
  • [8] Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2
    Boyoung Park
    James G. Dowty
    Choonghyun Ahn
    Aung K. Win
    Sung-Won Kim
    Min Hyuk Lee
    Jong Won Lee
    Eunyoung Kang
    John L. Hopper
    Sue K. Park
    [J]. Breast Cancer Research and Treatment, 2015, 152 : 659 - 665
  • [9] HIGHER FREQUENCY OF GERMLINE BRCA1 AND BRCA2 MUTATIONS IN AFRICAN AMERICAN PROSTATE CANCER
    Petrovics, Gyorgy
    Ravindranath, Lakshmi
    Chen, Yongmei
    Ying, Kai
    Ali, Amina
    Young, Denise
    McLeod, David
    Sesterhenn, Lsabell
    Rosner, Inger
    Dahut, William
    Srivastava, Shiv
    Dean, Michael
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E548 - E548
  • [10] Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
    Zlowocka-Perlowska, Elzbieta
    Toloczko-Grabarek, Aleksandra
    Narod, Steven A.
    Lubinski, Jan
    [J]. HEREDITARY CANCER IN CLINICAL PRACTICE, 2022, 20 (01)